Drug resistance in HIV-1

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 582-589

  Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; ETRAVIRINE; INTEGRASE; INTEGRASE INHIBITOR; MARAVIROC; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA POLYMERASE; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DEVELOPED COUNTRY; DRUG EFFICACY; ENVELOPE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 82955198409     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.020     Document Type: Review

References (75)

1. D.R. Kuritzkes, R.L. Bassett, J.D. Hazelwood, H. Barrett, R.A. Rhodes, R.K. Young, and V.A. Johnson Rate of thymidine analog resistance mutation accumulation with zidovudine- or stavudine-based regimens J AIDS 36 2004 600 603 (Pubitemid 38544509)
2. J.M. Whitcomb, N.T. Parkin, C. Chappey, N.S. Hellman, and C.J. Petropoulos Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates J Infect Dis 188 2003 992 1000 (Pubitemid 37268249)
3. R.M. Plank, and D.R. Kuritzkes An update on HIV-1 antiretroviral resistance Curr Opin HIV AIDS 1 2006 417 423
4. J.E. Gallant, S. Staszewski, A.L. Pozniak, E. DeJesus, J.M. Suleiman, M.D. Miller, D.F. Coakley, B. Lu, J.J. Toole, and A.K. Cheng Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2004 191 201 (Pubitemid 38917996)
5. J.E. Gallant, E. DeJesus, J.R. Arribas, A.L. Pozniak, B. Gazzard, R.E. Campo, B. Lu, D. McColl, S. Chuck, and J. Enejosa Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
6. E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, K. Mollan, C. Budhathoki, C. Godfrey, N.C. Jahed, L. Myers, and D. Katzenstein Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV type-1: a randomized trial Ann Intern Med 2011
7. D. Kempf, M.S. King, B. Bernstein, P. Cernohous, E. Bauer, J. Moseley, K. Gu, A. Hsu, S. Brun, and E. Sun Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine J Infect Dis 189 2004 51 60 (Pubitemid 38122329)
8. S. Walmsley, A. Avihingsanon, J. Slim, D.J. Ward, K. Ruxrungtham, J. Brunetta, U.F. Bredeek, D. Jayaweera, C.J. Guittari, and P. Larson Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults J Acquir Immune Defic Syndr 50 2009 367 374
9. R. Ortiz, E. DeJesus, H. Khanlou, E. Voronin, J. van Lunzen, J. Andrade-Villanueva, J. Fourie, S. De Meyer, M. De Pauw, and E. Lefebvre Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
10. S.A. Riddler, R. Haubrich, A.G. DiRienzo, L. Peeples, W.G. Powderly, K.L. Klingman, K.W. Garren, T. George, J.F. Rooney, and B. Brizz Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2008 2095 2106 (Pubitemid 351679596)
11. J. Friend, N. Parkin, T. Liegler, J.N. Martin, and S.G. Deeks Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen AIDS 18 2004 1965 1966 (Pubitemid 39313216)
12. M. Nijhuis, A.M. Wensing, W.F. Bierman, D. de Jong, R. Kagan, A. Fun, C.A. Jaspers, K.A. Schurink, M.A. van Agtmael, and C.A. Boucher Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V J Infect Dis 200 2009 698 709
13. H.S. Weinstock, I. Zaidi, W. Heneine, D. Bennett, J.G. Garcia-Lerma, J.M. Douglas Jr., M. LaLota, G. Dickinson, S. Schwarcz, and L. Torian The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities J Infect Dis 189 2004 2174 2180 (Pubitemid 38757188)
14. L.A. Wheeler, R. Trifonova, V. Vrbanac, E. Basar, S. McKernan, Z. Xu, E. Seung, M. Deruaz, T. Dudek, and J.I. Einarsson Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras J Clin Invest 121 2011 2401 2412
15. J. Vercauteren, A.M. Wensing, D.A. van de Vijver, J. Albert, C. Balotta, O. Hamouda, C. Kucherer, D. Struck, J.C. Schmit, and B. Asjo Transmission of drug-resistant HIV-1 is stabilizing in Europe J Infect Dis 200 2009 1503 1508
16. C.B. Hicks, P. Cahn, D.A. Cooper, S.L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M.A. Johnson, D. Neubacher, D. Mayers, and H. Valdez Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Lancet 368 2006 466 475 (Pubitemid 44142769)
17. B. Clotet, N. Bellos, J.M. Molina, D. Cooper, J.C. Goffard, A. Lazzarin, A. Wohrmann, C. Katlama, T. Wilkin, and R. Haubrich Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials Lancet 369 2007 1169 1178 (Pubitemid 46541620)
18. A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, A. Moll, W. Towner, B. Trottier, M. Peeters, and J. Vingerhoets Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48 (Pubitemid 47017467)
19. J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, A. Mills, G. Pialoux, T. Wilkin, M. Peeters, and J. Vingerhoets Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38 (Pubitemid 47017466)
20. R.T. Steigbigel, D.A. Cooper, P.N. Kumar, J.E. Eron, M. Schechter, M. Markowitz, M.R. Loutfy, J.L. Lennox, J.M. Gatell, and J.K. Rockstroh Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 2008 339 354
21. R.M. Gulick, J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlsson, and M. Wohlfeiler Maraviroc for previously treated patients with R5 HIV-1 infection N Engl J Med 359 2008 1429 1441
22. Y. Yazdanpanah, C. Fagard, D. Descamps, A.M. Taburet, C. Colin, B. Roquebert, C. Katlama, G. Pialoux, C. Jacomet, and C. Piketty High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial Clin Infect Dis 49 2009 1441 1449
23. R. Paredes, and B. Clotet Clinical management of HIV-1 resistance Antiviral Res 85 2010 245 265
24. K. Andries, H. Azijn, T. Thielemans, D. Ludovici, M. Kukla, J. Heeres, P. Janssen, B. De Corte, J. Vingerhoets, R. Pauwels, and M.P. de Bethune TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1 Antimicrob Agents Chemother 48 2004 4680 4686 (Pubitemid 39577672)
25. H. Azijn, I. Tirry, J. Vingerhoets, M.P. de Bethune, G. Kraus, K. Boven, D. Jochmans, E. Van Craenenbroeck, G. Picchio, and L.T. Rimsky TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1 Antimicrob Agents Chemother 54 2010 718 727
26. E.L. Asahchop, M. Oliveira, M.A. Wainberg, B.G. Brenner, D. Moisi, T. Toni, and C.L. Tremblay Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes Antimicrob Agents Chemother 55 2011 600 607
27. L. Tambuyzer, S. Nijs, B. Daems, G. Picchio, and J. Vingerhoets Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine J Acquir Immune Defic Syndr 2011
28. R. Kulkarni, K. Babaoglu, E.B. Lansdon, L. Rimsky, G. Picchio, M.D. Miller, and K.L. White Cross-talk between the HIV reverse transcriptase NRTI and NNRTI binding pockets: interactions between E138K and M184I and drug resistance Antivir Ther 16 2011 A21
29. J. Vingerhoets, L. Tambuyzer, H. Azijn, A. Hoogstoel, S. Nijs, M. Peeters, M.P. de Bethune, G. de Smedt, B. Woodfall, and G. Picchio Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies AIDS 24 2010 503 514
30. K.A. Delviks-Frankenberry, G.N. Nikolenko, and V.K. Pathak The "connection" between HIV drug resistance and RNase H Viruses 2 2010 1476 1503
31. S. Gupta, J. Vingerhoets, S. Fransen, L. Tambuyzer, H. Azijn, A. Frantzell, R. Paredes, E. Coakley, S. Nijs, and B. Clotet Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens Antimicrob Agents Chemother 55 2011 2872 2879
32. N. Sluis-Cremer, K. Moore, J. Radzio, S. Sonza, and G. Tachedjian N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations AIDS 24 2010 317 319
33. C.J. Cohen, J. Andrade-Villanueva, B. Clotet, J. Fourie, M.A. Johnson, K. Ruxrungtham, H. Wu, C. Zorrilla, H. Crauwels, and L.T. Rimsky Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Lancet 378 2011 229 237
34. L. Rimsky, J. Eron, and B. Clotet Characterization of the resistance profile of TMC278: 48-week analysis of the phase 3 studies ECHO and THRIVE 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 12-15, 2010. Boston: Abstract H-1810 2010
35. R. Schuurman, M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S.A. Danner, J. Mulder, C. Loveday, and C. Christopherson Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) J Infect Dis 171 1995 1411 1419
36. W. Keulen, N.T. Back, A. vanWijk, C.A.B. Boucher, and B. Berkhout Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase J Virol 71 1997 3346 3350 (Pubitemid 27121581)
37. Z. Hu, and D.R. Kuritzkes Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1 J Virol 85 2011 11309 11314
38. H.T. Xu, E.L. Asahchop, M. Oliveira, P.K. Quashie, Y. Quan, B.G. Brenner, and M.A. Wainberg Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations J Virol 85 2011 11300 11308
39. B. Roquebert, L. Blum, G. Collin, F. Damond, G. Peytavin, J. Leleu, S. Matheron, G. Chene, F. Brun-Vezinet, and D. Descamps Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen AIDS 22 2008 2045 2046
40. I. Malet, M. Wirden, S. Fourati, D. Armenia, B. Masquelier, L. Fabeni, S. Sayon, C. Katlama, C.F. Perno, and V. Calvez Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients J Antimicrob Chemother 66 2011 1481 1483
41. S. Fransen, S. Gupta, R. Danovich, D. Hazuda, M. Miller, M. Witmer, C.J. Petropoulos, and W. Huang Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways J Virol 83 2009 11440 11446
42. O. Delelis, S. Thierry, F. Subra, F. Simon, I. Malet, C. Alloui, S. Sayon, V. Calvez, E. Deprez, and A.G. Marcelin Impact of Y143 HIV-1 integrase mutations on resistance to Raltegravir in vitro and in vivo Antimicrob Agents Chemother 2009
43. J.L. Blanco, V. Varghese, S.Y. Rhee, J.M. Gatell, and R.W. Shafer HIV-1 integrase inhibitor resistance and its clinical implications J Infect Dis 203 2011 1204 1214
44. S. Fransen, M. Karmochkine, W. Huang, L. Weiss, C.J. Petropoulos, and C. Charpentier Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure Antimicrob Agents Chemother 53 2009 4522 4524
45. R.B. Ferns, S. Kirk, J. Bennett, I. Williams, S. Edwards, and D. Pillay The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy AIDS 23 2009 2159 2164
46. F. Canducci, M. Sampaolo, M.C. Marinozzi, E. Boeri, V. Spagnuolo, A. Galli, A. Castagna, A. Lazzarin, M. Clementi, and N. Gianotti Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies AIDS 23 2009 455 460
47. B. Young, S. Fransen, K.S. Greenberg, A. Thomas, S. Martens, M. St Clair, C.J. Petropoulos, and B. Ha Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy Antivir Ther 16 2011 253 256
48. R. Mukherjee, S.T. Jensen, F. Male, K. Bittinger, R.L. Hodinka, M.D. Miller, and F.D. Bushman Switching between raltegravir resistance pathways analyzed by deep sequencing AIDS 25 2011 1951 1959
49. Z. Hu, and D.R. Kuritzkes Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness J Acquir Immune Defic Syndr 55 2010 148 155
50. R. Quercia, E. Dam, D. Perez-Bercoff, and F. Clavel Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes J Virol 83 2009 10245 10249
51. S. Reigadas, B. Masquelier, C. Calmels, M. Laguerre, E. Lazaro, M. Vandenhende, D. Neau, H. Fleury, and M.L. Andreola Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A Antimicrob Agents Chemother 55 2011 3187 3194
52. M. Metifiot, N. Vandegraaff, K. Maddali, A. Naumova, X. Zhang, D. Rhodes, C. Marchand, and Y. Pommier Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143 AIDS 25 2011 1175 1178
53. J.J. Eron Jr., J.K. Rockstroh, J. Reynes, J. Andrade-Villanueva, J.V. Ramalho-Madruga, L.G. Bekker, B. Young, C. Katlama, J.M. Gatell-Artigas, and J.R. Arribas Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial Lancet Infect Dis 2011
54. M. Kozal, S. Lupo, E. DeJesus, J.M. Molina, C. McDonald, F. Raffi, J. Benetucci, M. Mancini, R. Yang, and V. Wirtz The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTIand RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID in treatment-naive HIV-infected subjects [abstract THLBB204] 18th International AIDS Conference Vienna, Austria, July 18-23 2010
55. B. Taiwo, L. Zheng, S. Gallien, R.M. Matining, D.R. Kuritzkes, C.C. Wilson, B.I. Berzins, E.P. Acosta, B. Bastow, P.S. Kim, and J.J. Eron Jr. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) AIDS 25 2011 2113 2122
56. J. Liu, M.D. Miller, R.M. Danovich, N. Vandergrift, F. Cai, C.B. Hicks, D.J. Hazuda, and F. Gao Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment Antimicrob Agents Chemother 55 2011 1114 1119
57. O. Goethals, R. Clayton, M. Van Ginderen, I. Vereycken, E. Wagemans, P. Geluykens, K. Dockx, R. Strijbos, V. Smits, and A. Vos Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors J Virol 82 2008 10366 10374 (Pubitemid 352691161)
58. H. Hatano, H. Lampiris, S. Fransen, S. Gupta, W. Huang, R. Hoh, J.N. Martin, J. Lalezari, D. Bangsberg, C. Petropoulos, and S.G. Deeks Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy J Acquir Immune Defic Syndr 54 2010 389 393
59. M. Kobayashi, T. Yoshinaga, T. Seki, C. Wakasa-Morimoto, K.W. Brown, R. Ferris, S.A. Foster, R.J. Hazen, S. Miki, and A. Suyama-Kagitani In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrob Agents Chemother 55 2011 813 821
60. B. Clotet, C. Katlama, J. Lalezari, B. Young, J. Huang, M.R. Underwood, M. Ait-Khaled, and W.G. Nichols HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for subjects experiencing virologic failure on raltegravir (RAL) in the VIKING study (ING112961) Antivir Ther 15 2010 A61
61. A.M. Tsibris, and D.R. Kuritzkes Chemokine antagonists as therapeutics: focus on HIV-1 Annu Rev Med 58 2007 445 459 (Pubitemid 46706526)
62. G. Fätkenheuer, M. Nelson, A. Lazzarin, I. Konourina, A.I. Hoepelman, H. Lampiris, B. Hirschel, P. Tebas, F. Raffi, and B. Trottier Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection N Engl J Med 359 2008 1442 1455
63. R.M. Gulick, Z. Su, C. Flexner, M.D. Hughes, P.R. Skolnik, T.J. Wilkin, R. Gross, A. Krambrink, E. Coakley, and W.L. Greaves Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211 J Infect Dis 196 2007 304 312 (Pubitemid 47047471)
64. M. Westby, M. Lewis, J. Whitcomb, M. Youle, A.L. Pozniak, I.T. James, T.M. Jenkins, M. Perros, and R.E. van der Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir J Virol 80 2006 4909 4920
65. M. Koot, I.P.M. Keet, A.H.V. Vos, R.E.Y. de Goede, M.T.L. Roos, R.A. Couthinho, F. Miedema, P.T.A. Schellekens, and M. Tersmette Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS Ann Intern Med 118 1993 681 688 (Pubitemid 23118038)
66. A.M. Tsibris, B. Korber, R. Arnaout, C. Russ, C.C. Lo, T. Leitner, B. Gaschen, J. Theiler, R. Paredes, and Z. Su Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo PLoS ONE 4 2009 e5683
67. J.P. Moore, and D.R. Kuritzkes A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors Curr Opin HIV AIDS 4 2009 118 124
68. M. Westby, C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry J Virol 81 2007 2359 2371
69. R.A. Ogert, L. Ba, Y. Hou, C. Buontempo, P. Qiu, J. Duca, N. Murgolo, P. Buontempo, R. Ralston, and J.A. Howe Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc J Virol 83 2009 12151 12163
70. T.J. Henrich, A.M. Tsibris, N.R. Lewine, I. Konstantinidis, K.E. Leopold, M. Sagar, and D.R. Kuritzkes Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate J Acquir Immune Defic Syndr 55 2010 420 427
71. P. Pugach, A.J. Marozsan, T.J. Ketas, E.L. Landes, J.P. Moore, and S.E. Kuhmann HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry Virology 361 2007 212 228 (Pubitemid 46551222)
72. R. Berro, R.W. Sanders, M. Lu, P.J. Klasse, and J.P. Moore Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry PLoS Pathog 5 2009 e1000548
73. P. McNicholas, Y. Wei, J. Whitcomb, W. Greaves, T.A. Black, C.L. Tremblay, and J.M. Strizki Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial J Infect Dis 201 2010 1470 1480
74. J.C. Tilton, C.B. Wilen, C.A. Didigu, R. Sinha, J.E. Harrison, C. Agrawal-Gamse, E.A. Henning, F.D. Bushman, J.N. Martin, S.G. Deeks, and R.W. Doms A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5 J Virol 84 2010 10863 10876
75. R.A. Ogert, Y. Hou, L. Ba, L. Wojcik, P. Qiu, N. Murgolo, J. Duca, L.M. Dunkle, R. Ralston, and J.A. Howe Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5 Virology 400 2010 145 155